BioVie Completes Bezisterim ADDRESS-LC Phase 2 Long COVID Treatment Phase; Topline Data Expected Before End of September 2026
BioVie Inc. (NASDAQ: BIVI) announced Monday August 31, 2026 completion of the last on-treatment visit in the ADDRESS-LC Phase 2 trial evaluating Bezisterim (a small-molecule insulin-sensitizer developed for the treatment of neurological symptoms of Long COVID). The Phase 2 study enrolled approximately 200 patients to evaluate whether Bezisterim can reduce brain fog, fatigue, and other lingering neurological symptoms after SARS-CoV-2 infection, and is fully funded by a grant from the U.S. Department of War (formerly Department of Defense). With the last patient's treatment visit complete and the one-month virtual follow-up nearly complete, BioVie anticipates topline results before end of September 2026. Not a peptide, but the readout is relevant to the peptide-industry Long COVID pipeline (LSALT peptide, BPC-157 for post-viral inflammation) and reflects the broader Department of War / BARDA interest in post-acute infection syndrome treatments.